NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXXEL is a fixed-dose combination tablet containing enalapril maleate (ACE inhibitor) and felodipine (calcium channel blocker) for oral use. It is indicated for hypertension management in patients who require dual antihypertensive therapy. The combination provides complementary mechanisms: enalapril inhibits angiotensin II formation while felodipine relaxes vascular smooth muscle.
LOE Approaching
As LOE approaches with moderate competitive pressure (30), brand teams are likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEXXEL offers limited career growth opportunities given its LOE-approaching status and zero linked job openings. Roles on this brand are primarily defensive, focused on market protection and managed decline rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on LEXXEL at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.